Distinct BAL cytokine signatures define immunopathological endotypes in interstitial lung disease
- 1Group of Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain
- 2Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 3Radiology Department, Hospital Santa Creu i Sant Pau, Universitat Autónoma Barcelona (UAB), Barcelona, Spain
Abstract
Background: Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by variable clinical phenotypes and dysregulated immune responses. The marked diversity in disease behavior and therapeutic response suggests the existence of distinct molecular endotypes. In this study, we applied an unsupervised clustering analysis to bronchoalveolar lavage (BAL) cytokines to identify clinically meaningful ILD subpopulations.
Methods: BAL cytokine data from ILD patients were analyzed using K-means clustering, identifying four primary clusters: (C1) TGF-β/IL-17A dominant, (C2) IL-6 dominant, (C3) IL-35/IL-10 dominant, and (C4) lacking a dominant cytokine signature. Immune cell composition, clinical characteristics, and disease progression were compared across clusters.
Results: Clusters C1 and C2 were associated with greater fibrotic burden. C1, characterized by elevated TGF-β and IL-17A levels, showed a higher prevalence of idiopathic pulmonary fibrosis (IPF) and increased BAL macrophages. C2, with high IL-6, included a higher proportion of smoke-related ILD (SR-ILD) and was associated with increased cardiovascular comorbidities, hospitalizations, and BAL neutrophils. In contrast, C3 and C4, with higher IL-35 and IL-10, were associated with lower fibrosis severity and a greater proportion of connective tissue disease-associated ILD (CTD-ILD). C3 and C4 showed more favorable clinical outcomes and disease stability over one year; notably, only C3 maintained stability over two years and exhibited increased BAL CD4+ T cells.
Conclusion: Clustering of BAL cytokine profiles revealed distinct immunological endotypes in ILD that correlated with fibrosis severity, clinical phenotype, and disease trajectory. This approach holds promise for improving patient stratification and prediction of disease progression in ILD.
Related
- Bronchoalveolar cytokine profiling identifies distinct endotypes in severe recurrent wheeze of infancy [Letter]
- Blood Cytokine Profiling Reveals Distinct Inflammatory Signatures in Phenotypes A and B of Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly PCOS).
- Candidate molecular endotypes and dynamic risk prediction in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a systematic scoping review
- INTEGRATED IMMUNOPHENOTYPING REVEALS DISTINCT MULTICOMPARTMENT IMMUNE SIGNATURES ASSOCIATED WITH CYTOKINE RELEASE SYNDROME FOLLOWING ANTI-CD19 CAR-T CELL THERAPY
- Pediatric critical illness endotypes reveal distinct outcomes and immune pathways shared across cause of illness
BibTeX
@article{osunagomez2026distinct,
title = {{Distinct BAL cytokine signatures define immunopathological endotypes in interstitial lung disease}},
author = {Rubén Osuna-Gómez and Ana Pardessus and Maria Mulet and Marta Hernández Marcos and Mᵅ Àngels Ortiz and Virginia Pajares and Elisabet Cantó and Joel Francesqui and José Manuel Brenes and Albert Guinart-Cuadra and Silvia Vidal and Diego Castillo},
journal = {Frontiers in Physiology},
year = {2026},
month = oct,
doi = {10.3389/fphys.2026.1951891},
url = {https://doi.org/10.3389/fphys.2026.1951891},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Distinct BAL cytokine signatures define immunopathological endotypes in interstitial lung disease
AU - Rubén Osuna-Gómez
AU - Ana Pardessus
AU - Maria Mulet
AU - Marta Hernández Marcos
AU - Mᵅ Àngels Ortiz
AU - Virginia Pajares
AU - Elisabet Cantó
AU - Joel Francesqui
AU - José Manuel Brenes
AU - Albert Guinart-Cuadra
AU - Silvia Vidal
AU - Diego Castillo
PY - 2026
DA - 2026/10/13
JO - Frontiers in Physiology
DO - 10.3389/fphys.2026.1951891
UR - https://doi.org/10.3389/fphys.2026.1951891
AB - Background: Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by variable clinical phenotypes and dysregulated immune responses. The marked diversity in disease behavior and therapeutic response suggests the existence of distinct molecular endotypes. In this study, we applied an unsupervised clustering analysis to bronchoalveolar lavage (BAL) cytokines to identify clinically meaningful ILD subpopulations. Methods: BAL cytokine data from ILD patients were analyzed using K-means clustering, identifying four primary clusters: (C1) TGF-β/IL-17A dominant, (C2) IL-6 dominant, (C3) IL-35/IL-10 dominant, and (C4) lacking a dominant cytokine signature. Immune cell composition, clinical characteristics, and disease progression were compared across clusters. Results: Clusters C1 and C2 were associated with greater fibrotic burden. C1, characterized by elevated TGF-β and IL-17A levels, showed a higher prevalence of idiopathic pulmonary fibrosis (IPF) and increased BAL macrophages. C2, with high IL-6, included a higher proportion of smoke-related ILD (SR-ILD) and was associated with increased cardiovascular comorbidities, hospitalizations, and BAL neutrophils. In contrast, C3 and C4, with higher IL-35 and IL-10, were associated with lower fibrosis severity and a greater proportion of connective tissue disease-associated ILD (CTD-ILD). C3 and C4 showed more favorable clinical outcomes and disease stability over one year; notably, only C3 maintained stability over two years and exhibited increased BAL CD4+ T cells. Conclusion: Clustering of BAL cytokine profiles revealed distinct immunological endotypes in ILD that correlated with fibrosis severity, clinical phenotype, and disease trajectory. This approach holds promise for improving patient stratification and prediction of disease progression in ILD.
SN - 1664-042X
ER -